Jun 2, 2026 at 11:49 AM#16
Dr.SurgeonPGH said:SUSTAIN-6 was the first CVOT to show cardiovascular benefit with semaglutide, relevant to cardiovascular risk.
Second this.
19 17zoe_NC, Dr.ObesityLA, NurseKim_ATL and 16 others
Reply Quote Save Share Report
Jun 2, 2026 at 6:09 PM#17
BiostatsBrad said:NNT calculation for cardiovascular risk clinical endpoints: NNT = 1/ARR (absolute risk reduction).
Thank you for spelling out the reasoning rather than just the conclusion.
20 18mike.trainer_LA, sarah_nash92, FitDadDave and 17 others
Reply Quote Save Share Report
Jun 3, 2026 at 12:29 AM#18
From the other side of the consultation, briefly.
BiostatsBrad said:...cardiovascular risk is just another fad...
I understand the skepticism — we've all seen "miracle" weight loss solutions come and go. But consider what makes GLP-1 agonists different:
- Phase 3 RCTs with thousands of participants (not 20-person pilot studies)
- Published in NEJM, JAMA, Lancet (not press releases)
- Replicated across multiple independent research groups
- Proven cardiovascular and renal benefits beyond weight loss
- Biological mechanism fully characterized at the receptor level
This isn't a fad — it's a new drug class supported by the highest level of clinical evidence. The comparison to past fads is understandable but inappropriate.
21 19Dr.EM_Chicago, pete_RVA, CarlaRPh_TPA and 18 others
Reply Quote Save Share Report
Sigma-Aldrich — Research-Grade Standards
Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.
Shop Reference StandardsJun 3, 2026 at 6:49 AM#19
Dr.BariatricHTX said:BiostatsBrad said: ...cardiovascular risk is just another fad...
Same experience, arrived at from the opposite direction.
Last edited: Jun 3, 2026 at 8:49 AM
22 20laura_annarbor, JenMemphis, pat_auckland and 19 others
Reply Quote Save Share Report